Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001181431-12-041138
Filing Date
2012-07-18
Accepted
2012-07-18 21:11:07
Documents
2
Period of Report
2012-07-18

Document Format Files

Seq Description Document Type Size
1 FORM 3 rrd351118.html 3  
1 FORM 3 rrd351118.xml 3 2216
2 POWER OF ATTORNEY rrd315052_355829.htm EX-24. 4634
  Complete submission text file 0001181431-12-041138.txt   8277
Mailing Address 89 HEADQUARTERS PLAZA NORTH 14TH FLOOR MORRISTOWN NJ 09760
Business Address 89 HEADQUARTERS PLAZA NORTH 14TH FLOOR MORRISTOWN NJ 09760 973-993-4867
Durata Therapeutics, Inc. (Issuer) CIK: 0001544116 (see all company filings)

EIN.: 871247903 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address DURATA THERAPEUTICS, INC. 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR MORRISTOWN NJ 07960
Business Address
Lack Jeremy David (Reporting) CIK: 0001554151 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35599 | Film No.: 12968885